Heron Therapeutics, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2022
The company expects full-year 2022 net product sales for the oncology care franchise in the range of $89 million to $93 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.23 USD | -1.82% | -10.28% | +90.00% |
Jun. 12 | Connect Biopharma Names New Chief Executive, Chair | MT |
May. 29 | Heron Therapeutics Submits Prior Approval Supplement to the FDA for Zynrelef Vial Access Needle | MT |
1st Jan change | Capi. | |
---|---|---|
+90.00% | 487M | |
+34.14% | 51.12B | |
-6.54% | 39.4B | |
+34.92% | 38.48B | |
+12.62% | 26.36B | |
-12.11% | 26.22B | |
-13.43% | 20.96B | |
+43.73% | 14.02B | |
+31.81% | 12.49B | |
-4.54% | 11.61B |